The FDA's Decisions Regarding New Indications for Approved Drugs
- 23 October 1996
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 276 (16) , 1342-1343
- https://doi.org/10.1001/jama.1996.03540160064035
Abstract
In this issue ofThe Journal, Dr Grossman and colleagues1criticize the use of sublingual nifedipine capsules in the treatment of hypertensive emergencies and pseudoemergencies. Sublingual nifedipine gained proponents because it is easy to use and rapidly lowers blood pressure, alleviating the concerns of the physician and staff. Recommendations to use sublingual nifedipine capsules have permeated the literature,2,3and such recommendations continue, even as recently as a letter4last month proposing that ancillary staff in nursing homes could draw up 0.1 mL of nifedipine into a syringe to administer orally to patients with "urgent needs for reduced blood pressure." Grossman et al point out that, in addition to the lack of evidence that an asymptomatic elevation in blood pressure should be lowered urgently and the considerable potential dangers of administering an oral drug for a hypertensive emergency, no studies have supported the use of sublingual nifedipine capsulesKeywords
This publication has 1 reference indexed in Scilit:
- Sublingual nifedipine for hypertensive emergenciesThe Lancet, 1991